Electron self-exchange in Pseudomonas cytochromes.

R. Timkovich,M. Cai,D. Dixon

DOI: https://doi.org/10.1016/0006-291X(88)90735-8

1988-02-15

Abstract:

What problem does this paper attempt to address?

[Comparative experimental research on the effects of cortisone & prednisone on blood coagulation].

D. Fumarola,F. Modica

1956-10-01

Abstract:
Residual tricuspid regurgitation after tricuspid transcatheter edge‐to‐edge repair: Insights into the EuroTR registry

Lukas Stolz,Karl‐Patrik Kresoja,Jennifer von Stein,Vera Fortmeier,Benedikt Koell,Wolfgang Rottbauer,Mohammad Kassar,Bjoern Goebel,Paolo Denti,Paul Achouh,Tienush Rassaf,Manuel Barreiro‐Perez,Peter Boekstegers,Andreas Rück,Philipp M. Doldi,Julia Novotny,Monika Zdanyte,Marianna Adamo,Flavien Vincent,Philipp Schlegel,Ralph‐Stephan von Bardeleben,Thomas J. Stocker,Ludwig T. Weckbach,Mirjam G. Wild,Stephanie Brunner,Stefan Toggweiler,Julia Grapsa,Tiffany Patterson,Holger Thiele,Tobias Kister,Mathias H. Konstandin,Eric Van Belle,Marco Metra,Tobias Geisler,Rodrigo Estévez‐Loureiro,Peter Luedike,Nicole Karam,Francesco Maisano,Philipp Lauten,Fabien Praz,Mirjam Kessler,Daniel Kalbacher,Volker Rudolph,Christos Iliadis,Philipp Lurz,Jörg Hausleiter,on behalf of the EuroTR Investigators,Roman Pfister,Stephan Baldus,Muhammed Gerçek,Felix Rudolph,Sebastian Ludwig,Christoph Pauschinger,Leonhard‐Moritz Schneider,Dominik Felbel,Carsten Salomon,Harald Lapp,Tania Puscas,Alain Berrebi,Amir Abbas Mahabadi,Florian Schindhelm,Berenice Caneiro‐Queija,Julio C Echarte,Jürgen Schreieck,Andreas Goldschmied,Edoardo Pancaldi,Daniela Tomasoni,Natacha Rousse,Samy Aghezzaf,Norbert Frey,Martin Kraus,Sebastian Rosch

DOI: https://doi.org/10.1002/ejhf.3274

2024-05-30

European Journal of Heart Failure

Abstract:Impact of residual tricuspid regurgitation (TR) after tricuspid transcatheter edge‐to‐edge repair (T‐TEER) (n = 1286). TV, tricuspid valve. Aims Data on the prognostic impact of residual tricuspid regurgitation (TR) after tricuspid transcatheter edge‐to‐edge repair (T‐TEER) are scarce. The aim of this analysis was to evaluate 2‐year survival and symptomatic outcomes of patients in relation to residual TR after T‐TEER. Methods and results Using the large European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR registry) we investigated the impact of residual TR on 2‐year all‐cause mortality and New York Heart Association (NYHA) functional class at follow‐up. The study further identified predictors for residual TR ≥3+ using a logistic regression model. The study included a total of 1286 T‐TEER patients (mean age 78.0 ± 8.9 years, 53.6% female). TR was successfully reduced to ≤1+ in 42.4%, 2+ in 40.0% and 3+ in 14.9% of patients at discharge, while 2.8% remained with TR ≥4+ after the procedure. Residual TR ≥3+ was an independent multivariable predictor of 2‐year all‐cause mortality (hazard ratio 2.06, 95% confidence interval 1.30–3.26, p = 0.002). The prevalence of residual TR ≥3+ was four times higher in patients with higher baseline TR (vena contracta >11.1 mm) and more severe tricuspid valve tenting (tenting area >1.92 cm2). Of note, no survival difference was observed in patients with residual TR ≤1+ versus 2+ (76.2% vs. 73.1%, p = 0.461). The rate of NYHA functional class ≥III at follow‐up was significantly higher in patients with residual TR ≥3+ (52.4% vs. 40.5%, p

cardiac & cardiovascular systems
Two-Year Outcomes for Tricuspid Repair With a Transcatheter Edge-to-Edge Valve Repair From the Transatlantic TRILUMINATE Trial

Ralph Stephan von Bardeleben,Philipp Lurz,Paul Sorajja,Tobias Ruf,Jörg Hausleiter,Marta Sitges,Jaqueline Da Rocha e Silva,Michael Näbauer,Marcel Weber,Gilbert H.L. Tang,Megan Heitkemper,Shih-Wa Ying,Jean-Noel Trochu,Saibal Kar,Rebecca T. Hahn,Georg Nickenig,Georg Nickenig,Ralph Stephan von Bardeleben,Martin Geyer,Peter Wenaweser,Patric Biaggi,Ioannis Kapos,Said Alsidawi,Philipp Lurz,Dabit Arzamendi,Regueiro Ander,Manuel Sabate,Anuradha Lala-Trindade,David Adams,Julie Swain,Mathias Orban,Jörg Hausleiter,Ottavio Alfieri,Eustachio Agricola,Matteo Montorfano,Jan-Malte Sinning,Alexander Tamm,Steffen Hoffmann,Marek Kowalski,Andrea Garatti,Alessandra Pecoraro,Gessica Motta,Maurizio Tusa,Michel Zuber,Stephan Windecker,Michael Samara,Karol Mudy,Sachin Parikh,Dee Dee Wang,Nicolas Piriou,Karl-Philipp Rommel,Christian Binner,Gustavo Jimenez,Xavier Freixa,Antonio Serra,David Lim,Stamatios Lerakis,Nicola Buzzatti,Marta Baragagna,Claudia Tiburtius,Carmelo Grasso,Federico De Marco,Francesco Maisano,Maurizio Taramasso,Richard Bae,Tiberio Frisoli,Patrice Guerin,Philipp Hartung,Sumeet Mitter,Noah Moss,Thomas Stocker,Francesco Ancona,Eustachio Agricola,Cristina Capogrosso

DOI: https://doi.org/10.1161/CIRCINTERVENTIONS.122.012888

2023-08-17

Abstract:Circulation: Cardiovascular Interventions, Volume 16, Issue 8, Page e012888, August 1, 2023. BACKGROUND:Tricuspid regurgitation (TR) is a common and progressive valve disease with significant mortality and hospitalization burden. Tricuspid transcatheter edge-to-edge repair provides a treatment option for high-risk patients with primary and secondary TR.METHODS:The TRILUMINATE trial ([Trial to Evaluate Treatment With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater Tricuspid Regurgitation]; n=85) is an international, prospective, single-arm, multicenter study to investigate the safety and performance of tricuspid transcatheter edge-to-edge repair with the TriClip implant in patients with symptomatic moderate or greater TR. Echocardiographic assessment was performed at a core laboratory. Outcomes included safety and clinical effectiveness and echocardiographic assessment of TR.RESULTS:At 2 years, TR was reduced to moderate or less in 60% of subjects, and reduction of at least 1 grade was achieved in 85.4% of subjects. TR reduction was sustained in 75% of the patients. While most metrics suggest the majority of favorable remodeling occurred within the first 30 days post-procedure, both right ventricular end diastolic diameter and tricuspid annular plane systolic excursion show signals of continued favorable remodeling through 2 years. Substantial improvements in 6-minute walking distance, New York Heart Association functional class, and Kansas City Cardiomyopathy Questionnaire score were sustained from 30 days to 2 years. Even with low rates of cardiovascular mortality (15.3%) and all-cause mortality (18.7%) noted at 2 years, all-cause hospitalization rate decreased from 1.30 events per patient-year 1 year before device implantation to 0.66 events per patient-year 2 years after the TriClip procedure, representing a reduction of 49% (P<0.0001).CONCLUSIONS:Tricuspid transcatheter edge-to-edge repair using the TriClip implant was found to be safe and effective, with sustained benefits at 2 years in subjects with symptomatic moderate or greater TR. Repair efficacy was durable at 2 years in 75% of the patients.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: NCT03227757.

cardiac & cardiovascular systems
A comparison of multiple reinforcer assessments to identify the function of maladaptive behavior.

S. Lindauer,J. Zarcone,D. Richman,S. Schroeder

DOI: https://doi.org/10.1901/JABA.2002.35-299

2002-09-01

Journal of Applied Behavior Analysis

Abstract:Functional analysis results indicated that maladaptive behaviors displayed by a 25-year-old man with profound mental retardation were maintained by attention from caregivers and possibly, to a lesser degree, by access to tangible items. A concurrent-schedules procedure was then used to study the relative reinforcing value for maladaptive behavior of attention versus tangible items. Results of the concurrent-schedules assessment and subsequent functional communication training indicated that preference for attention versus access to a tangible object varied.
Residual tricuspid regurgitation after transcatheter tricuspid valve edge-to-edge repair: the EuroTR Registry

L Stolz,P Lurz,C Iliadis,V Rudolph,D Kalbacher,M Kessler,F Praz,P Lauten,F Maisano,N Karam,P Luedike,R Estevez-Loureiro,M Metra,H Thiele,J Hausleiter

DOI: https://doi.org/10.1093/eurheartj/ehae666.1933

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Background Data on the prognostic impact of residual tricuspid regurgitation (TR) after transcatheter tricuspid valve edge-to-edge repair (T-TEER) are scarce. Purpose The aim of this analysis was to evaluate two-year survival and symptomatic outcomes of patients in relation to residual TR after T-TEER. Methods Using the large European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR Registry) we investigated the impact of residual TR on two-year all-cause mortality and New York Heart Association (NYHA) functional class at follow-up. The study further identified predictors for residual TR ≥3+ using a logistic regression model. Results The study included a total of 1286 T-TEER patients (53.6% females, mean age 78.0 ± 8.9 years). TR was successfully reduced to ≤1+ in 42.4%, 2+ in 40.0% and 3+ in 14.9% of patients at discharge, while 2.8% remained with TR ≥4+ after the procedure. Residual TR ≥3+ was an independent multivariable predictor of two-year all-cause mortality (hazard ratio 2.06, confidence interval 1.30-3.26, p=0.002, Figure 1). The prevalence of residual TR ≥3+ was 4-times higher in patients with higher baseline TR (vena contracta > 11.1 mm) and more severe TV tenting (tenting area >1.92 cm2) (Figure 2). Of note, no survival difference was observed in patients with residual TR ≤1+ vs. 2+ (76.2% vs. 73.1%, p=0.461). The rate of NYHA functional class ≥ III at follow-up was significantly higher in patients with residual TR ≥3+ (52.4% vs. 40.5%, p<0.001). Of note, the degree of TR reduction significantly correlated with the extend of symptomatic improvement (p=0.012). Conclusions T-TEER effectively reduced TR severity in the majority of patients. While residual TR ≥3+ was associated with worse outcomes, no differences were observed for residual TR 1+ vs. 2+. Symptomatic improvement correlated with the degree of TR reduction.Figure 1- Residual TR after T-TEERFigure 2 - Predicting residual TR

cardiac & cardiovascular systems
Transcatheter edge-to-edge repair of the tricuspid valve: The US experience

Ramy Sedhom,Michael Megaly,Marwan Saad,Ayman Elbadawi,Christian F Witzke,Santiago Garcia,Azeem Latib,Sameer A Gafoor

DOI: https://doi.org/10.1002/ccd.30141

Abstract:Objectives: To examine the trends in utilization and outcomes of tricuspid valve (TV) transcatheter edge-to-edge repair (TEER). Background: Surgery for isolated tricuspid regurgitation is associated with high morbidity and mortality and is rarely performed. TV TEER is an attractive alternative. Methods: The Nationwide Readmissions Database was queried using the International Classification of Diseases, 10th Revision, procedure code for TV TEER for years 2016-2019. The main outcomes were trends in utilization and in-hospital all-cause mortality. Results: We identified 918 hospitalizations for TV TEER. There was an uptrend in its utilization from 13 cases in the first quarter of 2016 to 122 cases in the last quarter of 2019 (p trend < 0.001). Concomitant mitral valve (MV) TEER was performed in 42.1% of admissions. The overall in-hospital mortality was 2.1%. Surgical TV replacement was needed in 1.1% of admissions; none of them died during the index hospitalization. Unplanned rehospitalizations were common at 30 days (15.7%); 38.2% of those were due to heart failure. There was no difference in in-hospital mortality between isolated TV TEER and combined MV and TV TEER (1.7% vs. 2.6%, p = 0.359). However, admissions receiving combined procedure had lower length of stay and urgent readmission rate. Conclusion: The current study showed that there was an increase in the utilization of TV TEER over 2016-2019 in the United States. TV TEER was associated with low rates of in-hospital mortality; however, the rate of urgent readmission remains high, mainly due to heart failure.
Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge-to-edge repair - Results from the TriValve registry

Giulio Russo,Luigi P Badano,Marianna Adamo,Hannes Alessandrini,Martin Andreas,Daniel Braun,Kim A Connelly,Paolo Denti,Rodrigo Estevez-Loureiro,Neil Fam,Mara Gavazzoni,Rebecca T Hahn,Claudia Harr,Joerg Hausleiter,Dominique Himbert,Daniel Kalbacher,Edwin Ho,Azeem Latib,Edith Lubos,Sebastian Ludwig,Philipp Lurz,Vanessa Monivas,Georg Nickenig,Daniela Pedicino,Giovanni Pedrazzini,Alberto Pozzoli,Denise Pires Marafon,Roberta Pastorino,Fabien Praz,Joseph Rodes-Cabau,Christian Besler,Joachim Schofer,Andrea Scotti,Kerstin Piayda,Horst Sievert,Gilbert H L Tang,Holger Thiele,Florian Schlotter,Ralph Stephan von Bardeleben,John Webb,Stephan Windecker,Martin Leon,Francesco Maisano,Marco Metra,Maurizio Taramasso

DOI: https://doi.org/10.1002/ejhf.3075

Abstract:Aim: Functional or secondary tricuspid regurgitation (STR) is the most common phenotype of tricuspid regurgitation (TR) with atrial STR (ASTR) and ventricular STR (VSTR) being recently identified as two distinct entities. Data on tricuspid transcatheter edge-to-edge repair (T-TEER) in patients with STR according to phenotype (i.e. ASTR vs. VSTR) are lacking. The aim of this study was to assess characteristics and outcomes of patients with ASTR versus VSTR undergoing T-TEER. Methods and results: Patients with STR undergoing T-TEER were selected from the Transcatheter Tricuspid Valve Therapies (TriValve) registry. ASTR was defined by (i) left ventricular ejection fraction ≥50%, (ii) atrial fibrillation, and (iii) systolic pulmonary artery pressure <50 mmHg. Patients not matching these criteria were classified as VSTR. Patients with primary TR and cardiac implantable electronic device were excluded. Key endpoints included procedural success and survival at follow-up. A total of 298 patients were enrolled in the study: 65 (22%) with ASTR and 233 (78%) with VSTR. Procedural success was similar in the two groups (80% vs. 83% for ASTR vs. VSTR, p = 0.56) and TEER was effective in reducing TR in both groups (from 97% of patients with baseline TR ≥3+ to 23% in ASTR and to 15% in VSTR, all p = 0.001). At 12-month follow-up, survival was significantly higher in the ASTR versus VSTR cohort (91% vs. 72%, log-rank p = 0.02), with VSTR being an independent predictor of mortality at multivariable analysis (hazard ratio 4.75). Conclusions: In a real-world, multicentre registry, T-TEER was effective in reducing TR grade in both ASTR and VSTR. At 12-month follow-up, ASTR showed better survival than VSTR.
Mitral regurgitation evolution after transcatheter tricuspid valve interventions - a sub-analysis of the TriValve Registry

Francesco Cannata,Alessandro Sticchi,Giulio Russo,Kamil Stankowski,Rebecca T Hahn,Hannes Alessandrini,Martin Andreas,Daniel Braun,Kim A Connelly,Paolo Denti,Rodrigo Estevez-Loureiro,Neil Fam,Claudia Harr,Joerg Hausleiter,Dominique Himbert,Daniel Kalbacher,Marianna Adamo,Azeem Latib,Edith Lubos,Sebastian Ludwig,Philipp Lurz,Vanessa Monivas,Georg Nickenig,Giovanni Pedrazzini,Alberto Pozzoli,Fabien Praz,Josep Rodes-Cabau,Karl-Philipp Rommel,Joachim Schofer,Horst Sievert,Gilbert Tang,Holger Thiele,Karl-Patrik Kresoja,Marco Metra,Ralph Stephan von Bardeleben,John Webb,Stephan Windecker,Martin Leon,Francesco Maisano,Federico De Marco,Gianluca Pontone,Maurizio Taramasso

DOI: https://doi.org/10.1093/ehjci/jeae227

2024-08-27

Abstract:Aims: Transcatheter tricuspid valve interventions (TTVI) are increasingly used to treat patients with significant tricuspid regurgitation (TR). The evolution of concurrent mitral regurgitation (MR) severity after TTVI is currently unknown and may be pivotal for clinical decision-making. The aim of this study was to assess the evolution of MR after TTVI and to identify predictors of MR worsening and improvement. Methods and results: This analysis is a substudy of the Trivalve Registry, an international registry designed to collect data on TTVI. This substudy included all patients with echocardiographic data on MR evolution and excluded those with a concomitant tricuspid and mitral transcatheter valve intervention or with a history of mitral valve intervention. The co-primary outcomes were MR improvement and worsening at two timepoints: pre-discharge and 2-month follow-up. This analysis included 359 patients with severe TR, mostly(80%) treated with tricuspid transcatheter edge-to-edge repair(T-TEER). MR improvement was found in 106(29.5%) and 99(34%) patients, while MR worsening in 34(9.5%) and 33(11%) patients at pre-discharge and 2-month follow-up, respectively. Annuloplasty and heterotopic replacement were associated with MR worsening. Independent predictors of MR improvement were: atrial fibrillation, T-TEER, acute procedural success, TR reduction, LVEDD>60 mm and beta-blocker therapy. Patients with moderate-to-severe/severe MR following TTVI showed significantly higher death rates. Conclusion: MR degree variation is common after TTVI, with most cases showing improvement. Clinical and procedural characteristics may predict the MR evolution, in particular procedural success and T-TEER play key roles in MR outcomes. TTVI may be beneficial even in the presence of functional MR.
Congestion patterns in severe tricuspid regurgitation and transcatheter treatment: Insights from a multicentre registry

Karl‐Philipp Rommel,Guillaume Bonnet,Vera Fortmeier,Lukas Stolz,Anne R. Schöber,Jennifer von Stein,Mohammad Kassar,Muhammed Gerçek,Sebastian Rosch,Thomas J. Stocker,Maria I. Körber,Karl‐Patrik Kresoja,Tanja K. Rudolph,Roman Pfister,Stephan Baldus,Stephan Windecker,Holger Thiele,Fabien Praz,Jörg Hausleiter,Volker Rudolph,Daniel Burkhoff,Philipp Lurz

DOI: https://doi.org/10.1002/ejhf.3235

2024-04-05

European Journal of Heart Failure

Abstract:Congestion patterns in transcatheter tricuspid valve interventions. AP, annuloplasty; HR, hazard ratio; RAP, right atrial pressure; RAPm, mean right atrial pressure; PCWP, pulmonary capillary wedge pressure; RHC, right heart catheterization; TEER, transcatheter edge‐to‐edge repair; TR, tricuspid regurgitation; TTVR, transcatheter tricuspid valve repair. Aims While invasively determined congestion holds mechanistic and prognostic significance in acute heart failure (HF), its role in patients with tricuspid regurgitation (TR)‐related right‐ heart failure (HF) undergoing transcatheter tricuspid valve intervention (TTVI) is less well established. A comprehensive understanding of congestion patterns might aid in procedural planning, risk stratification, and the identification of patients who may benefit from adjunctive therapies before undergoing TTVI. The aim of this study was to investigate the role of congestion patterns in patients with severe TR and its implications for TTVI. Methods and results Within a multicentre, international TTVI registry, 813 patients underwent right heart catheterization (RHC) prior to TTVI and were followed up to 24 months. The median age was 80 (interquartile range 76–83) years and 54% were women. Both mean right atrial pressure (RAP) and pulmonary capillary wedge pressure (PCWP) were associated with 2‐year mortality on Cox regression analyses with Youden index‐derived cut‐offs of 17 mmHg and 19 mmHg, respectively (p

cardiac & cardiovascular systems
Edge-to-edge repair for tricuspid valve regurgitation: 1-year follow up and clinical implications from the TR- Interventional Study (TRIS)

M Carpenito,V De Luca,V Cammalleri,M Piscione,G Antonelli,D Gaudio,F Coletti,E Nobile,A Strumia,A L Di Pumpo,S Mega,M Carassiti,F Grigioni,G P Ussia

DOI: https://doi.org/10.1093/eurheartj/ehae666.132

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Background Tricuspid regurgitation (TR) affects 7% of the population, contributing significantly to heart failure-related hospitalizations. Traditional treatments have several limitations, prompting the exploration of innovative interventions. Purpose The present study aims to investigate the efficacy of tricuspid valve transcatheter edge-to-edge repair (T-TEER) in real-world patients with severe and symptomatic TR deemed at high surgical risk. Primary objectives focus on assessing T-TEER-induced TR reduction and reverse structural remodeling of the RV. Secondary objectives include assessment of functional status, quality of life, and residual regurgitation during the 12-month follow-up period. Methods The TR-Interventional study (TRIS) is a prospective, single-arm study. From January 2021 to December 2023, we enrolled 44 symptomatic patients with at least severe TR referred for TEER. Outcomes included safety and effectiveness along with assessment of clinical status. Results The study cohort had a mean age of 78.3±7 years, with 77.3% women and a mean TRISCORE of 5.1±1.9. Seventeen patients (38.6%) had massive, 7 (15.9%) had torrential, and 20 (45.5%) patients had severe TR. Etiologies included functional (40.9%), degenerative (13.64%), lead-induced (15.9%), and mixed (29.54%) origin. The primary efficacy endpoint, which assesses the successful implantation and performance of the device at the 30-day mark, was attained in 82.9% of patients. The secondary efficacy endpoint, assessing the stability of TR reduction at the 12-month, was achieved in 82,3% of patients. Post-procedural TR reduction of at least 2 degrees was achieved in 84% of patients. Echocardiographic assessments indicate ongoing beneficial remodeling over the one-year follow-up (Figure 1). Effects on RV remodeling also became apparent at the one-year follow-up, including reductions in the RV end-diastolic basal (p<0.01) and medium (p= 0.04) diameters of the TA septal-lateral diameter (p< 0.01). Significant reduction in vena contracta width (9 mm to 3 mm; p=<0.01), regurgitant volume (58 ml to 30 ml; p<0.01), and effective regurgitant orifice area (EROA) (0.6 cm2 to 0.3 cm2; p<0.01), occurred between baseline and one-year follow-up (Figure 2). The NYHA Functional Class and KCCQ scores were improved from 30 days to 1 year (Figure 2). Conclusion TRIS suggests that T-TEER is a durable, effective, and safe therapeutic option for high-risk patients with severe TR. The enduring nature of TR reduction at one year correlates with sustained clinical benefits and reverse structural remodeling of the right ventricle.TR reductionNYHA and functional status

cardiac & cardiovascular systems
Prediction of Mortality and Heart Failure Hospitalization After Transcatheter Tricuspid Valve Interventions: Validation of TRISCORE

Marianna Adamo,Giulio Russo,Matteo Pagnesi,Edoardo Pancaldi,Hannes Alessandrini,Martin Andreas,Luigi P Badano,Daniel Braun,Kim A Connelly,Paolo Denti,Rodrigo Estevez-Loureiro,Neil Fam,Mara Gavazzoni,Rebecca T Hahn,Claudia Harr,Joerg Hausleiter,Dominique Himbert,Daniel Kalbacher,Edwin Ho,Azeem Latib,Edith Lubos,Sebastian Ludwig,Laura Lupi,Philipp Lurz,Vanessa Monivas,Georg Nickenig,Daniela Pedicino,Giovanni Pedrazzini,Alberto Pozzoli,Denise Pires Marafon,Roberta Pastorino,Fabien Praz,Joseph Rodes-Cabau,Christian Besler,Anne Rebecca Schöber,Joachim Schofer,Andrea Scotti,Kerstin Piayda,Horst Sievert,Gilbert H L Tang,Alessandro Sticchi,David Messika-Zeitoun,Holger Thiele,Florian Schlotter,Ralph Stephan von Bardeleben,John Webb,Julien Dreyfus,Stephan Windecker,Martin Leon,Francesco Maisano,Marco Metra,Maurizio Taramasso

DOI: https://doi.org/10.1016/j.jcin.2024.02.013

2024-04-08

Abstract:Background: Data on the prognostic role of the TRI-SCORE in patients undergoing transcatheter tricuspid valve intervention (TTVI) are limited. Objectives: The aim of this study was to evaluate the performance of the TRI-SCORE in predicting outcomes of patients undergoing TTVI. Methods: TriValve (Transcatheter Tricuspid Valve Therapies) is a large multicenter multinational registry including patients undergoing TTVI. The TRI-SCORE is a risk model recently proposed to predict in-hospital mortality after tricuspid valve surgery. The TriValve population was stratified based on the TRI-SCORE tertiles. The outcomes of interest were all-cause death and all-cause death or heart failure hospitalization. Procedural complications and changes in NYHA functional class were also reported. Results: Among the 634 patients included, 223 patients (35.2%) had a TRI-SCORE between 0 and 5, 221 (34.8%) had 6 or 7, and 190 (30%) had ≥8 points. Postprocedural blood transfusion, acute kidney injury, new atrial fibrillation, and in-hospital mortality were more frequent in the highest TRI-SCORE tertile. Postprocedure length of stay increased with a TRI-SCORE increase. A TRI-SCORE ≥8 was associated with an increased risk of 30-day all-cause mortality and all-cause mortality and the composite endpoint assessed at a median follow-up of 186 days (OR: 3.00; 95% CI: 1.38-6.55; HR: 2.17; 95% CI: 1.78-4.13; HR: 2.08, 95% CI: 1.57-2.74, respectively) even after adjustment for procedural success and EuroSCORE II or Society of Thoracic Surgeons Predicted Risk of Mortality. The NYHA functional class improved across all TRI-SCORE values. Conclusions: In the TriValve registry, the TRI-SCORE has a suboptimal performance in predicting clinical outcomes. However, a TRISCORE ≥8 is associated with an increased risk of clinical events and a lack of prognostic benefit after successful TTVI.
Impact of Tricuspid Regurgitation on Outcomes of Transcatheter Aortic Valve Replacement With Balloon-Expandable Valves

Firas Zahr,Sammy Elmariah,Sreekanth Vemulapalli,Susheel K Kodali,Rebecca T Hahn,Allen S Anderson,Mackram F Eleid,Charles J Davidson,Rahul P Sharma,William W O'Neill,Brian Bethea,Vinod H Thourani,Tarun Chakravarty,Aakriti Gupta,Raj R Makkar

DOI: https://doi.org/10.1016/j.jcin.2024.07.005

2024-08-26

Abstract:Background: Tricuspid regurgitation (TR) is highly prevalent in the transcatheter aortic valve replacement (TAVR) population, but clear management guidelines are lacking. Objectives: The aims of this study were to elucidate the prevalence and consequences of severe TR in patients with aortic stenosis undergoing TAVR and to examine the change in TR post-TAVR, including predictors of improvement and its impact on longer term mortality. Methods: Using Centers for Medicare and Medicaid Services-linked TVT (Transcatheter Valve Therapy) Registry data, a propensity-matched analysis was performed among patients undergoing TAVR with baseline mild, moderate, or severe TR. Kaplan-Meier estimates were used to assess the impact of TR on 3-year mortality. Multivariable analysis identified predictors of 30-day TR improvement. Results: Of the 312,320 included patients, 84% had mild, 13% moderate, and 3% severe TR. In a propensity-matched cohort, severe baseline TR was associated with higher in-hospital mortality (2.5% vs 2.1% for moderate TR and 1.8% for mild TR; P = 0.009), higher 1-year mortality (24% vs 19.6% for moderate TR and 16.6% for mild TR; P < 0.0001), and 3-year mortality (54.2% vs 48.5% for moderate TR and 43.3% for mild TR; P < 0.0001). Among the patients with severe TR at baseline, 76.4% improved to moderate or less TR 30 days after TAVR. Baseline mitral regurgitation moderate or greater, preserved ejection fraction, higher aortic valve gradient, and better kidney function predicted TR improvement after TAVR. However, severe 30-day residual TR was associated with higher 1-year mortality (27.4% vs 18.7% for moderate TR and 16.8% for mild TR; P < 0.0001). Conclusions: Severe baseline and 30-day residual TR after TAVR are associated with increased mortality up to 3 years. This analysis identifies a higher risk group that could be evaluated for the recently approved tricuspid interventions.
Key Echocardiographic Considerations for Tricuspid Valve Transcatheter Edge-to-Edge Repair.

Ravinay Bhindi,Christopher Choong,Sara L. Hungerford,Eleanor E. Rye,Peter S. Hansen

DOI: https://doi.org/10.1016/j.echo.2023.01.013

IF: 7.722

2023-02-08

Journal of the American Society of Echocardiography

Abstract:Chronic tricuspid regurgitation (TR) results in progressive right ventricular (RV) volume overload, followed by right-sided chamber dilatation, RV systolic dysfunction and eventual low-output cardiac failure. Severe TR is associated with considerable morbidity and mortality, and yet until recently, patients in the late stage of their disease course had limited treatment options. Cognisant of the high mortality rates associated with surgical intervention, tricuspid valve (TV) transcatheter edge-to-edge repair (TEER) has emerged as a promising solution for patients with severe TR. As has been learnt from the transcatheter mitral valve TEER experience, detailed morphological and mechanistic assessment of the TV with transthoracic and transoesophageal imaging are essential to optimal patient selection and procedural success. The current review will provide a comprehensive overview of tricuspid valvular anatomy, the updated mechanistic classification of TR and key echocardiographic considerations in the evaluation, management and follow-up of patients undergoing TV TEER.

cardiac & cardiovascular systems
Outcomes of Transcatheter Tricuspid Edge-to-Edge Repair in Patients With Right Ventricular Dysfunction

Johanna Vogelhuber,Tetsu Tanaka,Refik Kavsur,Tadahiro Goto,Can Öztürk,Miriam Silaschi,Georg Nickenig,Sebastian Zimmer,Marcel Weber,Atsushi Sugiura

DOI: https://doi.org/10.1161/circinterventions.123.013156

2024-04-19

Circulation Cardiovascular Interventions

Abstract:Circulation: Cardiovascular Interventions, Ahead of Print. BACKGROUND:We assessed the safety profile of tricuspid transcatheter edge-to-edge repair (TEER) in patients with right ventricular (RV) dysfunction.METHODS:We identified patients undergoing TEER to treat tricuspid regurgitation from June 2015 to October 2021 and assessed tricuspid annular plane systolic excursion (TAPSE) and RV fractional area change (RVFAC). RV dysfunction was defined as TAPSE <17 mm and RVFAC <35%. The primary end point was 30-day mortality after TEER. We also investigated the change in the RV function in the early phase and clinical outcomes at 2 years.RESULTS:The study participants (n=262) were at high surgical risk (EuroSCORE II, 6.2% [interquartile range, 4.0%–10.3%]). Among them, 44 patients met the criteria of RV dysfunction. Thirty-day mortality was 3.2% in patients with normal RV function and 2.3% in patients with RV dysfunction (P=0.99). Tricuspid regurgitation reduction to ≤2+ was consistently achieved irrespective of RV dysfunction (76.5% versus 70.5%;P=0.44). TAPSE and RVFAC declined after TEER in patients with normal RV function (TAPSE, 19.0±4.7 to 17.9±4.5 mm;P=0.001; RVFAC, 46.2%±8.1% to 40.3%±9.7%;P<0.001). In contrast, those parameters were unchanged or tended to increase in patients with RV dysfunction (TAPSE, 13.2±2.3 to 15.3±4.7 mm;P=0.011; RVFAC, 29.6%±4.1% to 31.6%±8.3%;P=0.14). Two years after TEER, compared with patients with normal RV function, patients with RV dysfunction had significantly higher mortality (27.0% versus 56.3%;P<0.001).CONCLUSIONS:TEER was safe and feasible to treat tricuspid regurgitation in patients with RV dysfunction. The decline in the RV function was observed in patients with normal RV function but not in patients with RV dysfunction.

cardiac & cardiovascular systems
[Augmentation ileocystoplasty in neurogenic bladder due to transverse myelitis in a woman with systemic lupus erythematosus].

S. Kato,Yasuhisa Ito,Y. Nishino,Y. Ban,T. Deguchi

2005-10-01

Abstract:A 39-year-old female with systemic lupus erythematosus (SLE) with a neurogenic bladder is described. She developed voiding disturbance with paraplegia and sensory disturbance on her inferior limb. Clinical findings suggested elevated activities of SLE with transverse myelitis. Although her symptoms were improved after one course of methylprednisolone pulse therapy, clean intermittent catheterization was required for urinary incontinence and residual urine. One year later, bilateral hydronephrosis and vesical diverticulitis developed, and thus augmentation ileocystoplasty was performed. After three months of the operation, hydronephrosis and urinary incontinence resolved with frequent clean intermittent catheterization. We should not overlook lower urinary tract symptoms in patients with SLE. We advocate performing a surgical procedure in cases in which conservative treatments are not effective.
Mitral valve gradient changes associate with outcomes of patients undergoing transcatheter edge-to-edge repair

Roni Sraya,Itshak Amsalem,Shemy Carasso,Or Gilad,Elad Asher,Danny Dvir,Emanuel Harari,Michael Glikson,David Marmor,Mony Shuvy

DOI: https://doi.org/10.1016/j.ijcard.2024.131766

IF: 4.039

2024-01-11

International Journal of Cardiology

Abstract:Introduction Transcatheter edge-to-edge repair (TEER) is typically used to treat mitral regurgitation (MR) in patients with high surgical risk. Increased post-procedural mitral valve gradient (MVG) may impact mortality and hospitalizations. We aim to evaluate and compare the absolute postprocedural MVG and the change in the MVG effect on outcomes for patients undergoing TEER therapy. Methods Patients who underwent TEER for severe MR were divided into two groups, initially by postprocedural absolute MVG, TTE-based at discharge, and then by the difference between preprocedural and postprocedural MVG. Primary endpoints included all-cause mortality and heart failure hospitalization (HFH) during one year after the procedure. Results The study included 100 patients. The mean MVG increased from 3.39 mmHg immediately after the procedure to 4.83 mmHg the following day, an increase of 1.44 mmHg ( p < 0.001). First stratification was by MVG on the day following the procedure - MVG ≤5 mmHg ( n = 70) and MVG >5 mmHg ( n = 30). There was no significant difference in rates of survival (88.6%, 93.3%, p = 0.716) or HFH (18.6%, 33.3%, p = 0.178). Second stratification was by the difference in preprocedural and postprocedural MVG- delta MVG <3 mmHg ( n = 55) and delta MVG ≥3 mmHg ( n = 45). While survival rates did not significantly differ (87.3% vs. 93.3%, p = 0.503), delta MVG ≥3 mmHg correlated with higher HFH rates (12.7% vs. 35.6%, p = 0.014). Conclusions The MVG of patients undergoing TEER usually increases on the day after the procedure compared to the immediate post-procedure MVG. Higher delta MVG is associated with higher HFH rate.

cardiac & cardiovascular systems
Transcatheter tricuspid valve repair in the setting of heart failure with preserved or reduced left ventricular ejection fraction

Karl‐Patrik Kresoja,Alexander Lauten,Mathias Orban,Karl‐Philipp Rommel,Brunilda Alushi,Christian Besler,Daniel Braun,Matthias Unterhuber,Karl Stangl,Ulf Landmesser,Steffen Massberg,Holger Thiele,Jörg Hausleiter,Philipp Lurz

DOI: https://doi.org/10.1002/ejhf.1975

2020-09-02

European Journal of Heart Failure

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Aims</h3><p>Severe tricuspid regurgitation (TR) impairs prognosis in patients with left‐sided heart failure (HF) with preserved (≥50%, HFpEF) and reduced ejection fraction (<50%, HFrEF). Transcatheter tricuspid valve leaflet edge‐to‐edge repair (TTVR) potentially improves prognosis among patients with severe TR. We sought to assess the impact of left‐sided HF types on outcomes of TTVR.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods and Results</h3><p>In this retrospective study 71 HFpEF and 40 HFrEF patients, defined according to the European Society of Cardiology criteria, with isolated TR treated by TTVR, in two tertiary care centres, between 2016 and 2019 were analysed. The primary outcome was a composite outcome of all‐cause mortality, HF hospitalization at 12 months (median follow‐up 238[IQR175‐365]days). Additionally, a propensity score matching with a conservatively treated cohort of 914 patients with severe TR was performed.</p><p>Procedural success did not differ between HFpEF (mean age 75.9 ± 9.3 years) or HFrEF (mean age 74.7 ± 9.1 years) patients (86% vs. 78%,p = 0.299). The primary endpoint occurred more frequently in patients with HFrEF as compared to HFpEF (50 vs. 30%,p = 0.016). Procedural success was associated with a reduced occurrence of the primary endpoint among patients with HFpEF (p < 0.001) but not HFrEF (p = 0.813), while both groups showed improvement in New York Heart Association functional class (both p < 0.001).</p><p>After matching for age, EuroSCORE II, presence of an RV‐lead and systolic pulmonary artery pressure, successful TTVR was associated with lower mortality as compared to conservative therapy in HFpEF patients (p = 0.020), but not in HFrEF patients (p = 0.274).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>TTVR might be a therapeutic option in patients with severe TR and HFpEF compared to conservative therapy.</p><p>This article is protected by copyright. All rights reserved.</p></section>

cardiac & cardiovascular systems
Most Hospitalized Patients with Significant Tricuspid Regurgitation Have Advanced Disease Preventing Transcatheter Tricuspid Valve Intervention

Allison O. Dumitriu Carcoana,Christopher B. Scoma,Sebastian N. Maletz,Jose A. Malavet,Daniela R. Crousillat,Fadi A. Matar,Dumitriu Carcoana,A. O.,Scoma,C.,Maletz,S.,Malavet,J.,Crousillat,D. R.,Matar,F.

DOI: https://doi.org/10.1101/2023.09.14.23295588

2023-09-16

MedRxiv

Abstract:Background: More than moderate tricuspid regurgitation (TR) is associated with high mortality. Surgical tricuspid valve repair and replacements are rarely performed due to high operative mortality risk, mainly attributed to late presentation. Novel transcatheter tricuspid valve intervention (TTVI) devices are being developed as an alternative to surgery. The population of patients presenting to tertiary care centers who can benefit from TTVI has not been well defined. Our objective was to study the characteristics of these patients and to define the sub-population who may be candidates for TTVI. Methods: We analyzed 12,677 consecutive 2D echocardiograms completed at our tertiary care center between March 2021 and March 2022 and identified 581 inpatients with more than moderate TR. Clinical and echocardiographic data were collected by individual chart review. The 2021 European Society of Cardiology (ESC) guidelines on the management of valvular disease are currently the only guidelines that include TTVI. We used these guidelines to retrospectively assign the 581 patients to medical therapy, surgery, or TTVI treatment. Results: 470 patients (80.9%) were assigned to medical therapy, 57 (9.8%) were assigned to TTVI, and 54 (9.3%) were assigned to tricuspid valve surgery. Of note, 76.2% (443/581) of patients were precluded from any intervention due to advanced disease or anatomic ineligibility, and only 4.6% (27/581) presented too early for intervention, being both asymptomatic and without RV dilatation. Conclusion: Only 9.8 percent of patients presenting to a tertiary care center with significant TR would be hypothetical candidates for TTVI when these technologies are approved in the United States. Earlier identification and treatment of TR could increase the number of patients who may benefit from interventions including TTVI.
Transthoracic and transoesophageal echocardiography for tricuspid transcatheter edge-to-edge repair: a step-by-step protocol

Matteo Mazzola,Cristina Giannini,Alessandro Sticchi,Paolo Spontoni,Nicola Riccardo Pugliese,Luna Gargani,Marco De Carlo

DOI: https://doi.org/10.1093/ehjimp/qyae017

2024-03-21

Abstract:Tricuspid regurgitation (TR) carries an unfavourable prognosis and often leads to progressive right ventricular (RV) failure. Secondary TR accounts for over 90% of cases and is caused by RV and/or tricuspid annulus dilation, in the setting of left heart disease or pulmonary hypertension. Surgical treatment for isolated TR entails a high operative risk and is seldom performed. Recently, transcatheter edge-to-edge repair (TEER) has emerged as a low-risk alternative treatment in selected patients. Although the experience gained from mitral TEER has paved the way for the technique's adaptation to the tricuspid valve (TV), its anatomical complexity necessitates precise imaging. To this end, a comprehensive protocol integrating 2D and 3D imaging from both transthoracic echocardiography (TTE) and transoesophageal echocardiography (TOE) plays a crucial role. TTE allows for an initial morphological assessment of the TV, quantification of TR severity, evaluation of biventricular function, and non-invasive haemodynamic evaluation of pulmonary circulation. TOE, conversely, provides a detailed evaluation of TV morphology, enabling precise assessment of TR mechanism and severity, and represents the primary method for determining eligibility for TEER. Once a patient is considered eligible for TEER, TOE, alongside fluoroscopy, will guide the procedure in the catheterization lab. High-quality TOE imaging is crucial for patient selection and to achieve procedural success. The present review examines the roles of TTE and TOE in managing patients with severe TR eligible for TEER, proposing the step-by-step protocol successfully adopted in our centre.
Insight into tricuspid transcatheter edge-to-edge repair: no longer the forgotten valve

Rongfeng Xu,Zhenyu Cai,Jiandong Ding,Genshan Ma

DOI: https://doi.org/10.1080/14779072.2023.2286010

2023-01-01

Expert Review of Cardiovascular Therapy

Abstract:IntroductionTricuspid regurgitation (TR) is one of the most prevalent types of valvular heart disease linked to poor prognosis in patients with heart failure and is usually ignored. TR has received considerable attention due to the progressive advancements in transcatheter therapies in recent years.Areas coveredWith relatively solid data and rapid technological advancements, tricuspid transcatheter edge-to-edge repair (T-TEER) is the most frequently employed in a series of tricuspid transcatheter interventional treatments for TR. However, the efficacy and technical benefits of T-TEER are limited because of the unique anatomical characteristics and pathological mechanisms of the tricuspid valve. The aim of this review is to summarize reported data on current status of T-TEER and to provide an expert opinion regarding the challenges it is now experiencing and future development direction and approach.Expert opinionT-TEER is a significant treatment for TR, but its effectiveness and technical promotion are limited due to the tricuspid valve unique anatomical characteristics and pathological mechanisms. The selection criteria for suitable patients, the choice of when to intervene, device innovation, the advancement of ultrasound technology, and the volume of evidence in evidence-based medicine all indicate that the disorder of TR will eventually be better treated and understood.

Electron self-exchange in Pseudomonas cytochromes.

[Comparative experimental research on the effects of cortisone & prednisone on blood coagulation].

Residual tricuspid regurgitation after tricuspid transcatheter edge‐to‐edge repair: Insights into the EuroTR registry

Two-Year Outcomes for Tricuspid Repair With a Transcatheter Edge-to-Edge Valve Repair From the Transatlantic TRILUMINATE Trial

A comparison of multiple reinforcer assessments to identify the function of maladaptive behavior.

Residual tricuspid regurgitation after transcatheter tricuspid valve edge-to-edge repair: the EuroTR Registry

Transcatheter edge-to-edge repair of the tricuspid valve: The US experience

Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge-to-edge repair - Results from the TriValve registry

Mitral regurgitation evolution after transcatheter tricuspid valve interventions - a sub-analysis of the TriValve Registry

Congestion patterns in severe tricuspid regurgitation and transcatheter treatment: Insights from a multicentre registry

Edge-to-edge repair for tricuspid valve regurgitation: 1-year follow up and clinical implications from the TR- Interventional Study (TRIS)

Prediction of Mortality and Heart Failure Hospitalization After Transcatheter Tricuspid Valve Interventions: Validation of TRISCORE

Impact of Tricuspid Regurgitation on Outcomes of Transcatheter Aortic Valve Replacement With Balloon-Expandable Valves

Key Echocardiographic Considerations for Tricuspid Valve Transcatheter Edge-to-Edge Repair.

Outcomes of Transcatheter Tricuspid Edge-to-Edge Repair in Patients With Right Ventricular Dysfunction

[Augmentation ileocystoplasty in neurogenic bladder due to transverse myelitis in a woman with systemic lupus erythematosus].

Mitral valve gradient changes associate with outcomes of patients undergoing transcatheter edge-to-edge repair

Transcatheter tricuspid valve repair in the setting of heart failure with preserved or reduced left ventricular ejection fraction

Most Hospitalized Patients with Significant Tricuspid Regurgitation Have Advanced Disease Preventing Transcatheter Tricuspid Valve Intervention

Transthoracic and transoesophageal echocardiography for tricuspid transcatheter edge-to-edge repair: a step-by-step protocol

Insight into tricuspid transcatheter edge-to-edge repair: no longer the forgotten valve